---
title: "《业绩》中国罕王中期纯利 1.04 亿人民币跌 2.9%  不派息"
description: "中国罕王公布 6 月止六个月中期业绩，收入 14.05 亿人民币 (下同)，按年增加 10.8%。录得纯利 1.04 亿元，倒退 2.9%，每股盈利 5.4 分。不派息。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/253350214.md"
published_at: "2025-08-17T11:57:29.000Z"
---

# 《业绩》中国罕王中期纯利 1.04 亿人民币跌 2.9%  不派息

> 中国罕王公布 6 月止六个月中期业绩，收入 14.05 亿人民币 (下同)，按年增加 10.8%。录得纯利 1.04 亿元，倒退 2.9%，每股盈利 5.4 分。不派息。

中国罕王 (03788.HK) 公布 6 月止六个月中期业绩，收入 14.05 亿人民币 (下同)，按年增加 10.8%。录得纯利 1.04 亿元，倒退 2.9%，每股盈利 5.4 分。不派息。

### Related Stocks

- [03788.HK - 中国罕王](https://longbridge.com/zh-CN/quote/03788.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| China Hanking Holdings Ltd. joins MSCI China Small Cap Index | China Hanking Holdings Ltd. will be added to the MSCI China Small Cap Index after the February 2026 review. This inclusi | [Link](https://longbridge.com/zh-CN/news/275603658.md) |
| China Hanking to Raise HK$772 Million via Share Subscription, Placement | China Hanking to Raise HK$772 Million via Share Subscription, Placement | [Link](https://longbridge.com/zh-CN/news/273304973.md) |
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-CN/news/276024005.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-CN/news/275851575.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-CN/news/276016059.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。